• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    N

    National Health Service Wales

    EST. 1946
    1,033论文总数
    1.9万引用总数

    论文量&引用量时间轴

    机构学者

    论文(1033)

    年份
    起
    –
    止
    排序
    1Neuropsychological Outcome after Cardiac Arrest: Results from a Sub-Study of the Targeted Hypothermia Versus Targeted Normothermia after Out-of-hospital Cardiac Arrest (TTM2) Trial
    Erik Blennow Nordström,Susanna Vestberg,Lars Evald,Marco Mion,Magnus Segerström,Susann Ullén,John Bro‑Jeppesen,Hans Friberg,Katarina Heimburg,Anders M. Grejs,Thomas R. Keeble,Hans Kirkegaard,

    BackgroundThis study is designed to provide detailed knowledge on cognitive impairment after out-of-hospital cardiac arrest (OHCA) and its relation to associated factors, and to validate the neurocognitive screening of the Targeted Hypothermia versus Targeted Normothermia after Out-of-Hospital Cardiac Arrest trial (TTM2-trial), assessing effectiveness of targeted temperature management after OHCA.MethodsThis longitudinal multi-center clinical study is a sub-study of the TTM2-trial, in which a comprehensive neuropsychological examination is performed in addition to the main TTM2-trial neurocognitive screening. Approximately 7 and 24months after OHCA, survivors at selected study sites are invited to a standardized assessment, including performance-based tests of cognition and questionnaires of emotional problems, fatigue, executive function and insomnia. At 1:1 ratio, a matched control group from a cohort of acute myocardial infarction (MI) patients is recruited to perform the same assessment. We aim to include 100 patients per group. Potential differences between the OHCA patients and the MI controls at 7 and 24months will be analyzed with a linear regression, using composite z-scores per cognitive domain (verbal, visual/constructive, working memory, episodic memory, processing speed, executive functions) as primary outcome measures. Results from OHCA survivors on the main TTM2-trial neurocognitive screening battery will be compared with neuropsychological test results at 7months, using sensitivity and specificity analyses.DiscussionIn this study we collect detailed information on cognitive impairment after OHCA and compare this to a control group of patients with acute MI. The validation of the TTM2 neurocognitive screening battery could justify its inclusion in routine follow-up. Our results may have a potential to impact on the design of future follow-up strategies and interventions after OHCA.Trial registrationClinicalTrials.gov, NCT03543371. Registered 1 June 2018

    2026Critical Care(2026)引用:26
    引用
    AI阅读
    加入学术空间
    2Lecanemab Appropriate Use Recommendations for Clinical Practice in the UK
    Catherine J Mummery, Jill Rasmussen, Dan Blackburn, Elizabeth Coulthard, R Rhys Davies,Rachel Dorsey, Nick C Fox, Akram A Hosseini, Chineze Ivenso, Matthew Jones, Sean P Kennelly, Christopher Kipps,

    Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) in adults who are apolipoprotein E ε4 gene ( APOE4 ) heterozygotes or non-carriers. A group of UK neurologists, old age psychiatrists and geriatricians with expertise in AD convened to agree appropriate use recommendations for lecanemab in UK clinical practice. The primary focus of these recommendations is safety. Eligibility criteria for lecanemab in the UK include (a) a clinical diagnosis of MCI or mild dementia due to AD, (b) the presence of amyloid-β pathology, confirmed using approved methods (ie, an amyloid positron emission tomography scan or cerebrospinal fluid assay) and (c) APOE4 heterozygous or non-carrier status. Eligibility screening should be conducted in secondary care and those identified as being potentially eligible for lecanemab should be referred to a specialist centre for confirmation of the likely pathological diagnosis, APOE4 counselling and testing and a multidisciplinary consensus decision regarding treatment eligibility. Lecanemab is administered as an intravenous infusion every 2 weeks, and those eligible for treatment should have brain magnetic resonance imaging (MRI) scans prior to the 1st, 5th, 7th and 14th infusions. Specific guidance is provided for safety monitoring and management of potential adverse reactions, including amyloid-related imaging abnormalities and infusion-related reactions. The introduction of lecanemab into UK clinical practice provides an important opportunity to improve services for all people living with dementia, not just those eligible for lecanemab treatment.

    2026Journal of neurology, neurosurgery, and psychiatry(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Remote Consultations in Sexual and Reproductive Health Services: a Systematic Review of Evidence on Effectiveness, Cost-Effectiveness, Experiences, Access and Equity
    Charlotte Spurway,Iestyn Williams, Oluseyi Cyril Ayinde, Christian Bohm,Fiona Burns, Jo Gibbs, Jo Josh, Helen Munro,Melvina Woode Owusu, Danielle Solomon, Jonathan Dc Ross,Louise J Jackson

    OBJECTIVES:Timely access to sexual health screening and contraception is an important public health issue. Substantial funding reductions for sexual and reproductive health services (SRHS) and COVID-19 have led to significant changes in service delivery, including the rapid introduction of remote consultations, as a substitute for in-person contact. There is limited evidence relating to the barriers to remote consultations and how these may impact sexual health outcomes and wider health inequalities. This study synthesises existing evidence on remote consultations to examine effectiveness, cost-effectiveness, experiences, access and equity. METHODS:Eighteen electronic databases were systematically searched to locate relevant studies published from OECD (Organisation for Economic Co-operation and Development) countries after 2010. The Mixed Methods Appraisal Tool was used to evaluate the quality of the studies. RESULTS:Out of 8690 studies identified, 48 met the inclusion criteria. The included studies were heterogeneous and covered a range of topics; however, few focused on health inequalities and remote consultations, with satisfaction and quality of care being the most common outcome measures. Many of the studies were completed post-2020 in response to COVID-19 and were of medium to low quality. Access to technology and communication challenges were found to impact inequality when accessing SRHS via remote consultations, although they enhance convenience for service users and service providers. CONCLUSIONS:Overall, the review shows that a range of studies have investigated remote consultations in SRHS, but there remains limited evidence on the impact on health inequalities and sexual health outcomes. The surge in post-2020 research, spurred by COVID-19, indicates the necessity for further high-quality research into equitable SRHS delivery in the post-COVID era, particularly in addressing technological and communication barriers. There is a need to further optimise access and the delivery of remote consultations in SRHS, considering the needs of service users, and minimising inequality (observed differences) and inequity (unfair differences).CRD42023397288.

    2026Sexually transmitted infections(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Population-Based Cohort Study: Colorectal Cancer Risk Stratification in Symptomatic Patients Using the Faecal Immunochemical Test, Blood Results and Patient Characteristics in Wales
    Francesca Ligori Malcolm,Colin J. Crooks,Joe West,Manpreet Bains, Elliann Fairbairn,Jeff Turner, Benjamin Hughes, Lynnette Jones,David J. Humes

    Background Wales has the highest rate of colorectal cancer (CRC) in the UK. National guidelines recommend using the faecal immunochemical test (FIT) in patients presenting with symptoms of bowel cancer. FIT >= 10 mu gHb/g in symptomatic patients is presumed to indicate a > 3% risk of CRC. However, evidence from England and Scotland has found that the risk is lower in certain demographic groups. Aims To examine 1-year risk of CRC in Welsh patients with symptoms of suspected bowel cancer by demographics, iron deficiency anaemia (IDA), and FIT. Methods Cohort study of adults registered in the Welsh Longitudinal General Practice dataset with a FIT recorded from 01/01/2020-31/03/2024. Kaplan-Meier estimates were used to calculate 1-year cumulative risks of CRC. Results We included 166,863 patients with a FIT; 19.2% had a FIT >= 10 mu gHb/g. Within 1 year, 2864 (1.72%) were diagnosed with CRC; 90.2% of which were following FIT >= 10 mu gHb/g. A FIT cut-off of >= 10 mu gHb/g in isolation identified a > 3% risk of CRC across all age groups. In those with FIT >= 10 mu gHb/g, IDA resulted in an increase in predicted risk across all age groups. IDA aided stratification further in women < 50 years; risk of CRC was 6.45% (95% CI: 3.52-9.29) with a FIT >= 10 mu gHb/g and IDA compared to 2.20% (95% CI: 1.57-2.83) without IDA. Conclusions In Wales, the risk of CRC following FIT >= 10 mu gHb/g is higher than observed in English and Scottish cohorts. Stratification by demographics and blood results identified those at highest risk, but this did not fully explain the higher baseline risk observed in comparison to other UK nations.

    2026ALIMENTARY PHARMACOLOGY & THERAPEUTICS(2026)
    引用
    AI阅读
    加入学术空间
    5Evaluation of an Online Workshop for Parents/Carers of Children Who Stammer
    Anna Hill
    2026INTERNATIONAL JOURNAL OF LANGUAGE & COMMUNICATION DISORDERS(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 1033 篇论文

    合作机构(100)

    卡迪夫大学合作论文 160
    斯旺西大学合作论文 75
    Cardiff and Vale University Health Board,National Health Service Wales合作论文 62
    威尔士大学医院合作论文 60
    帝国理工学院合作论文 31
    Betsi Cadwaladr University Health Board,National Health Service Wales合作论文 31
    牛津大学合作论文 28
    Oxford University Hospitals NHS Trust合作论文 25
    伯明翰大学合作论文 24
    Cwm Taf Morgannwg University Health Board合作论文 22

    机构统计